Navigation Links
Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members
Date:11/11/2008

SAN JOSE, Calif., Nov. 11 /PRNewswire-USNewswire/ -- The CPF today announced that the Pulmonary Fibrosis Research Enhancement Act (PFREA) (H.R. 6567) - which would authorize $16 million in new federal funding for pulmonary fibrosis (PF) research - has now gained the support of 27 Members of the U.S. House of Representatives.

PFREA is first of its kind legislation to improve research and awareness of pulmonary fibrosis, a terminal lung disease with no known cause, no FDA approved treatment and no cure. (For more information on PF, visit http://www.coalitionforpf.org). The PFREA is expected to be re-introduced in the 111th Congress in early 2009. However, additional Members of Congress could be added on as co-sponsors in the current Congress if there is a lame duck Congressional session.

"We are pleased to see the Pulmonary Fibrosis Research Enhancement Act gaining momentum. This bill is critical to finding treatments and saving lives from this devastating disease," said Mishka Michon, Chief Executive Officer of the CPF. "We are thankful for the leadership Brian Baird and Mike Castle have given to this effort."

The PFREA was originally introduced in Congress on July 22, 2008 by Representative Brian Baird (D-WA) and Representative Mike Castle (R-DE). Congressman Baird lost his father to pulmonary fibrosis, and Congressman Castle lost his brother and sister to the devastating disease. A substantial portion of the $16 million authorization would be used to establish a comprehensive national registry of PF patients. The Act would also:

-- Mandate the creation of a National PF Action Plan, in conjunction with

the National Institutes of Health (NIH) and the Centers for Disease

Control (CDC), which would focus on strategies to improve public

awareness of PF, and accelerate patient and medical education

strategies. The Action Plan would be provided to the Director of the

NIH within one year of the Act's passage.

-- Establish a National PF Advisory Board, which would make recommendations

to the NIH and CDC concerning the structure and management of a PF

patient registry. The goal of the registry would be to improve

understanding of the cause(s) and progression of PF, improve standards

of care, accelerate research, and develop new therapies sooner.

-- Establish a National Summit on PF, to foster collaboration between

Federal Agencies, researchers, patients and advocates to identify new

approaches to research and treat PF. The Summit would be held every

three years.

To view the legislation in its entirety, please visit http://thomas.loc.gov/ and type in "Pulmonary Fibrosis Research Enhancement Act" in the search box for bills.

To date, the following Members of Congress have agreed to co-sponsor H.R. 6567:

-- Thomas Allen - Maine

-- Rob Bishop - Utah

-- Earl Blumenauer - Oregon

-- Dennis Cardoza - California

-- Mike Castle - Delaware

-- Nathan Deal - Georgia

-- Diana DeGette - Colorado

-- Jim Gerlach - Pennsylvania

-- Virgil Goode - Virginia

-- Bob Goodlatte - Virginia

-- Bart Gordan - Tennessee

-- Jane Harman- California

-- Marcy Kaptur - Ohio

-- Mark Kirk - Illinois

-- Tom Latham - Louisiana

-- Steven LaTourette - Ohio

-- Zoe Lofgen - California

-- Jim Marshall - Georgia

-- Bill Pascrell - New Jersey

-- David Price - North Carolina

-- Jackie Speier - California

-- John Tierney - Massachusetts

-- Henry Waxman - California

-- Peter Welch - Vermont

-- Robert Wexler - Florida

-- Frank Wolf - Virginia

-- C.W. "Bill" Young - Florida

The CPF is actively advocating for the Bill's passage, and is asking its 17,000 members, and all those who are affected by PF, to voice their support for HR 6567 by visiting http://www.coalitionforpf.org/cpf_advocacy.php and becoming a CPF advocate. By joining the ACT campaign, you will become part of an army of volunteers who are contacting Congress, national health policymakers and the media to educate them about the PF. Every three months, members will receive free the CPF's ACT Action Alert, a newsletter detailing the advocacy efforts and outlining ways you can help. The CPF's advocacy program allows you to easily contact your Member of Congress immediately to voice your support. For further information, please visit the CPF at http://www.coalitionforpf.org, call us at 888-222-8541, or email us at info@coalitionforpf.org.

About Pulmonary Fibrosis (PF)

IPF is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 17,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
2. Women at Higher Risk for Pulmonary Hypertension
3. Cialis May Help Ease Pulmonary Hypertension
4. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
5. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. The U.S. Surgeon General Issues National Call-to-Action on Deep-Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
7. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
8. American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act
9. Simple Case Management Cuts Pulmonary Disease Admissions
10. A guided broncoscope achieves biopsy of 75 percent pulmonary nodules without puncture or surgery
11. COPD patients benefit more from pulmonary rehab in earlier stages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is ... powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been ... pleased to be the first in Arkansas to introduce the most powerful SCS system ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of ... With the average cost of healthcare rising and the U.S. senior population expected to ... affordability of where they live. An annual 2017 report looked at a variety of ...
(Date:5/26/2017)... ... 2017 , ... via seating is proud to partner with ... specifically designed for clinical areas. Genie Copper Mesh is a crossover chair for ... provide customers with a game changing chair that is affordably priced,” Chas Hepler ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... will continue to be available at a discounted crowdfunding price on Indiegogo . ... they are, I also wanted to bring a fidget toy to the market that ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
Breaking Medicine Technology: